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background: The optimal treatment for rhabdomyosarcoma (rMs) requires multidisciplinary treatment with chemotherapy, 
surgery, and radiotherapy. surgery and radiotherapy are integral to the local control (Lc) of rMs. however, postsurgical and 
radiotherapy-related complications could develop according to the local therapy and tumor location. In this study, we con-
ducted a single-center analysis of the outcomes and toxicity of multidisciplinary treatment using proton beam therapy (pBT) 
for pediatric rMs. 
Materials and methods: rMs patients aged younger than 20 years whose rMs was newly diagnosed and who underwent pBT 
at University of Tsukuba hospital (UTh) during the period from 2009 to 2019 were enrolled in this study. The patients’ clinical 
information was collected by retrospective medical record review. 
results: Forty-eight patients were included. The 3-year progression-free survival (pFs) and overall survival (Os) rates of all 
the patients were 68.8% and 94.2%, respectively. The 3-year pFs rates achieved with radical resection, conservative resection, 
and biopsy only were 65.3%, 83.3%, and 67.6%, respectively (p = 0.721). The 3-year Lc rates achieved with radical resection, 
conservative resection, and biopsy only were 90.9%, 83.3%, and 72.9%, respectively (p = 0.548). Grade 3 or higher mucositis/
dermatitis occurred in 14 patients. although the days of opioid use due to mucositis/dermatitis during the chemotherapy with 
pBT were longer than those during the chemotherapy without pBT [6.1 and 1.6 (mean), respectively, p = 0.001], the frequencies 
of fever and elevation of c-reactive protein were equivalent. 
conclusions: Multidisciplinary therapy containing pBT was feasible and provided a relatively fair 3-year pFs, even in children 
with newly diagnosed rMs without severe toxicity.
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Introduction
The treatment of rhabdomyosarcoma (RMS) 
consists of a multidisciplinary approach includ-
ing surgery, radiotherapy, and intensive neoadju-
vant/adjuvant chemotherapy. Multiagent chemo-
therapy comprising vincristine, dactinomycin, and 
cyclophosphamide (VAC) is widely used for RMS. 
Local treatment of surgical achievement and ra-
diotherapy are two of the main survival prognostic 
factors for RMS. Total tumor removal is always 
the goal but in some cases is not possible owing to 
postoperative dysfunction of the vital organs. In 
particular, an initial radical surgery usually could 
not be achieved for parameningeal tumors of the 
head and neck or for genitourinary tumors of the 
bladder/prostate [1].
The progression-free survival (PFS) rates of 
RMS are 90%, 60–70%, and 20–30% for low-, in-
termediate-, and high-risk patients, respectively, 
whilst acute and long-term therapeutic toxicities 
can be substantial [2–4]. Long-term comorbidi-
ties such as organ dysfunction, retardation of 
growth and development, and secondary cancer 
are also a serious problem for childhood cancer 
survivors [5]. Particle therapy, including proton 
beam therapy (PBT), has unique physical proper-
ties that can reduce/eliminate the unnecessary ra-
diation doses to the surrounding normal tissues, 
which resulted in improvement of early and late 
treatment-induced toxicities [6]. Although, Mizu-
moto et al. [7] reported that radiation-induced 
toxicities occurred in 16% of pediatric patients 
during PBT, the evaluation of toxicity due to PBT 
only is very difficult. Radiotherapy was mostly 
conducted with chemotherapy in pediatric malig-
nancies, and concurrent chemotherapy influences 
the occurrence and severity of treatment-related 
toxicities [8]. Sufficient data on the feasibility of 
multimodal therapy containing PBT for pediatric 
RMS are required, and to the best of our knowl-
edge, comparison of the toxicities among multi-
modal treatments with/without PBT has not been 
previously assessed. 
Since April 2016, PBT for childhood malignant 
solid tumors has been covered in Japan by the pub-
lic health insurance system, and the number of pa-
tients who receive PBT is increasing. We conducted 
a retrospective cohort study to assess the feasibility 
of multidisciplinary therapy including PBT as well 
as the tumor prognosis in children with newly di-
agnosed RMS.
Materials and methods
Forty-eight consecutive patients aged younger 
than 20 years, whose RMS was newly diagnosed 
pathologically and who underwent PBT at UTH 
during the period from 2009 to 2019, were included. 
The patients’ clinical information was collected by 
retrospective medical record review and included 
the chemotherapy regimen, surgical information, 
PBT plan, therapy-related toxicity, and disease sta-
tus. The patients’ current condition and additional 
clinical information were collected from the local 
physicians or by mailing/telephone interview with 
the patients/families. 
Toxicities were evaluated using the Common 
Terminology Criteria for Adverse Events ver. 4.0 
[9]. Seven patients underwent the entire course of 
therapy at UTH, and we investigated the number 
of days of fever (> 38.0°C), the highest C-reactive 
protein (CRP) value, and the days of opioid use 
for each chemotherapy cycle with/without PBT. 
Delay in chemotherapy or PBT was defined as 8 
days or more.
The protocol for this study was in accordance 
with the Declaration of Helsinki and Ethical 
Guidelines for Medical and Health Research In-
volving Human Subjects of the Ministry of Edu-
cation, Culture, Sports, Science and Technology, 
and the Ministry of Health, Labor and Welfare of 
Japan and was approved by the ethics committee 
of UTH (H27-137). Written informed consent 
was obtained from the patients’ parents or guard-
ians, and informed assent that was appropriately 
arranged according to their age and ability to 
understand was also obtained from the patients 
themselves.
PFS was defined as the time from diagnosis 
until the first relapse, any death, or last patient 
contact, at which time the patient was censored. 
Overall survival (OS) was defined as the time 
from diagnosis until any death or last patient 
contact, at which time the patient was cen-
sored. PFS and OS were calculated using the 
Kaplan-Meier method. Frequency of toxicities 
was evaluated using the Mann-Whitney U test. 
All analyses were performed with SPSS ver. 26.0 
(SPSS, Chicago, IL). 




Forty-eight patients (26 boys) were included. 
The median age at diagnosis was 3.8 years (range, 
0.2–15.1 years). The details of characteristics of the 
patients are shown in Table 1.
Thirteen of the 48 patients (27%) underwent 
radical surgical resection. Eight of these patients 
(61%) achieved radical resection before PBT. Eight 
patients (17%) underwent conservative resection 
to preserve organ function. Twenty-seven patients 
(56%) received biopsy only because severe organ 
damage due to surgical removal was predicted.
The irradiation doses of the PBT are shown in 
Table 1. The median irradiation dose was 50.4 gray 
equivalent (GyE) (range, 41.4–59.4). The radiation 
dose was significantly higher in the nonsurgical 
treatment group (Fig. 1, p = 0.049). Proton beam 
therapy can avoid irradiation of the surrounding 
normal tissues and maintain the targeted dose to the 
tumor. Figure 2 shows the distribution of radiation 
doses that was planned with intensity-modulated 
radiation therapy (IMRT) and PBT in a patient with 
buttock and ilium RMS. Whilst with IMRT a large 
area of the pelvic cavity is irradiated with 30% of the 
total dose to the tumor bed, PBT avoids irradiation 
outside the target region. 
Toxicity
Acute toxicity: grade 3 mucositis, including cys-
titis, occurred in 12 patients in total; the irradiated 
tumor sites in these patients were the head and 
neck (6 patients), the genitourinary tract (4 pa-
tients), the perianal area (1 patient), and the retro-
peritoneum (1 patient) (Tab. 2). Grade 3 dermatitis 
occurred in 7 patients in total; the irradiated tu-














head and neck 24 (50)
Intracranial extension 3 (6)




transferred to UtH for Pbt
Yes 41 (85)
No 7 (15)
Follow-up period, median (range), years  3.3 (0.4–11.8)
chemotherapy concurrent with Pbt‡
Vc 40 (23)




radical resection 13 (27)
conservative resection 8 (17)
Biopsy only 27 (56)





UTh — University of Tsukuba hospital; pBT — proton beam therapy;  
Vc — vincristine and cyclophosphamide; Gye — gray equivalent. 
†diaphragm 2 — retroperitoneum 2 — perianal area 1 — bile duct 1.  
‡One patient started with platinum-containing therapy and switched  






















Figure 1. radiation dose according to surgical achievement. 
The doses of radiation are shown by box-and-whisker plots 
according to the surgical achievement. The median dose 
[Gye (range)] of each group was as follows: radical resection 
[n = 13, 50.4 (41.4–59.4)]; conservative resection [n = 8, 
50.4 (41.4–50.4)]; biopsy only [n = 27, 50.4 (45–61.4)]. The 
radiation dose was significantly higher in the biopsy only 
group (p = 0.049)
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mor sites in these patients were the head and neck 
(2 patients), the genitourinary tract (4 patients), 
and the perianal area (1 patient). There were no 
nonhematological grade 4 toxicities. Grade 3 or 4 
hematological toxicities occurred in 45 patients. 
Chemotherapy delay occurred in 4 patients: in all 
of these patients, the delay was due to delayed 
recovery from bone marrow suppression, and in 
1 patient, it was due to concurrent grade 3 muco-
sitis. Reduced chemotherapy dosage was selected 
by physicians because of severe mucositis in 4 pa-
tients, vincristine omission in 1 patient, delayed 
VAC with 50% reduction in cyclophosphamide in 
1 patient, 75% reduction in cyclophosphamide in 
1 patient, and irinotecan discontinuation in 1 pa-
tient. PBT interruption occurred in 2 of 7 patients 
with bladder RMS due to cystitis (interrupted for 
10 and 18 days, respectively), but both resumed 
receiving irradiation after recovery, completed the 
initially planned dose, and survived without dis-
ease progression at the last censored point. No 
patients required dose reduction in radiotherapy. 
Sixteen of the 48 patients undergoing PBT with 
chemotherapy (35%) needed opioid use for derma-
titis/mucositis (cystitis). Although 4 of the 5 blad-
der RMS patients treated with PBT with chemo-
therapy needed opioid use for cystitis, 2 patients 
with bladder irradiation undergoing PBT without 
chemotherapy did not need opioid use. Although 
41 of the 48 patients (85%) were transferred to our 
institution to receive PBT, no chemotherapy delay 
due to the transfer occurred in these patients.
Figure 2. Dose distribution according to proton beam therapy (pBT) and intensity-modulated radiotherapy (IMrT) in a 
patient with buttock and ilium rMs. representative dosimetry of normal tissue-sparing achieved pBT when compared with 
IMrT. pBT avoided irradiation to the right pelvic cavity bowel tract, bladder, and rectum, whereas with IMrT, a large area of 
the pelvic cavity was irradiated with 30% of the total dose to the tumor bed
table 2. Nonhematological acute toxicity of grade 3 or higher
Site of irradiated primary tumor 
Mucositis Dermatitis
Grade 3 Grade 4 Grade 3 Grade 4
head and neck (n = 24) 6 0 2 0
Genitourinary tract (n = 13) 4 0 4 0
Trunk (n = 3) 0 0 0 0
extremity (n = 2) 0 0 0 0
Others (n = 6) 2† 0 1‡ 0
†perianal area and retroperitoneum, respectively. ‡perianal area
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We conducted subgroup analysis to assess 
the PBT toxicities in each chemotherapy course 
with/without PBT in the 7 patients who received 
multimodal therapy from the beginning at UTH. 
The number of days of fever (> 38.0°C), the high-
est CRP value, and the period of days of opioid 
use in all 75 courses of chemotherapy alone and 
in all 18 courses of concurrent chemotherapy with 
PBT were assessed. The mean number of days of 
opioid use for severe pain due to dermatitis/muco-
sitis (cystitis) was significantly longer in the course 
of concurrent chemotherapy with PBT (1.6 vs. 
6.1 days, p = 0.001). The mean duration of fever 
(days) and the highest CRP value did not differ 
significantly between the 2 groups (p = 0.579 and 
p = 0.713, respectively; Tab. 3). Pain due to mu-
cositis was treated with indomethacin oral spray 
[10] and nonsteroidal anti-inflammatory drugs in 
addition to opioids according to the physicians’ 
choice for each patient. Nasogastric tube nutrition 
was applied in some severe cases (data not shown). 
Dermatitis was treated with topical steroid oint-
ment/petrolatum and application of appropriate 
skin protection materials.
Late toxicities
The number of patients and the time of late 
toxicities are shown in Table 4. Among the pa-
tients who received irradiation to head and neck 
RMS, tooth growth disorder developed in 4 pa-
tients; facial asymmetry, in 4 patients; trismus, 
in 2 patients; cataracts, in 5 patients; recurrent 
caries, in 2 patients; hypothyroidism, in 1 patient; 
growth hormone deficiency, in 1 patient; and re-
current otitis media, in 1 patient. Among those 
who received irradiation to genitourinary tract 
RMS, pollakiuria occurred in 2 patients, and ovar-
ian dysfunction, in 1 patient. One patient with 
diaphragm RMS developed myelodysplastic syn-
drome (MDS), which was considered to be a che-
motherapy-related toxicity.
Outcome
Thirty-six of the 48 patients (75%) had survived 
without disease progression at the time of the last 
follow-up. The median follow-up period was 3.3 
(range, 0.4–11.8) years. The 3-year PFS and OS 
rates in all the patients were 68.8% [95% confi-
dence interval (CI): 53.5–84.1%] and 94.2% (95% 
CI: 86.4–102%), respectively. In the intermediate- 
and high-risk groups, the 3-year PFS rates were 
72.4 % (95% CI: 56.9–87.9%) and 50.0% (95% 
CI: 10.0–0.90%), respectively. In the intermedi-
ate- and high-risk groups, the 3-year OS rates were 
97% (95% CI: 91.1–103%), and 83.3% (95% CI: 
53.5–113.1%), respectively (Tab. 5). Twelve patients 
(25%) (10: alveolar type; 2: embryonal type) re-
lapsed. Local relapse inside the irradiation field was 
observed in 7 of the 48 patients (15%). Local relapse 
outside the irradiation field, local relapse of both 
inside and outside the irradiation field, and intra-
table 3. comparison of  chemotherapy with and without pBT in terms of occurrence of acute toxicities
Cx alone Cx + PBT p
Number of chemotherapies, cycles 75 18  
Mean duration of fever per cycle, days 1.4 2.1 0.579
Mean value of highest crp in each cycle [mg/dL] 1.36 1.08 0.713
Mean days of opioid use per individual
Total 120 109
per each chemotherapy 1.6 6.1 0.001
crp — c-reactive protein; cx — chemotherapy; pBT —proton beam therapy






Tooth growth disorder 4 2, 4, 4, 6
Facial asymmetry 4 1, 3, 7, 7
Trismus 2 0, 0
cataracts 5 2, 2, 3, 3, 6
recurrent caries 2 2, 2
hypothroidism 1 2
Growth hormone deficiency 1 7
recurrent otitis media 1 2
pollakiuria 2 2, 6
Ovarian dysfuncrion 1 5
Myelodysplasia syndrome 1 2
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peritoneal dissemination relapse were observed in 
1 patient for each. Distant metastatic relapse was 
observed in 2 patients. Three patients died: two 
from disease progression and one from complica-
tions from hematopoietic stem cell transplantation 
for secondary MDS.
The 3-year outcomes by surgical status were as 
follows: the 3-year OS rates were 100% (95% CI: 
100–100%), 83.3% (95% CI: 53.5–113.1%), and 
95.2% (95% CI: 86.2–104.2%) in the radical re-
section, conservative resection, and biopsy only 
groups, respectively (p = 0.47). The 3-year PFS rates 
were 65.3% (95% CI: 37.5–93.1%), 83.3% (95% CI: 
53.5–113.1%) and 67.6% (95% CI: 47.6–87.6%) in 
the radical resection, conservative resection, and 
biopsy only groups, respectively (p = 0.72), and 
no significant differences were found among them 
(Fig. 3B). The 3-year local control (LC) rates were 
90.9% (95% CI: 73.9–107.9%), 83.3% (95% CI: 
53.7–112.9%), and 72.9% (95% CI: 54.6–91.2%) 
(p = 0.548) in the radical resection, conservative re-
section, and biopsy only groups, respectively, which 
revealed a tendency of a higher 3-year LC rate in 
the radical resection group (Fig. 3C).
Discussion
RMS occurs most frequently in the head and 
neck, in approximately one-third of all patients, fol-
lowed by the genitourinary tract and the extremities 
[11]. In our study, the rate of head and neck RMS 
was 50%, which is higher than those of previous 
reports (Tab. 1). This higher rate may be due to the 
low possibility of tumor removal by surgery given 
that the head and neck contain many vital organs; 
therefore, more patients with tumors in the head 
and neck than patients with tumors in other sites 
were transferred to UTH for PBT, which reduces 
unnecessary radiation exposure to the surround-
ing tissues as compared with conventional photon 
beam therapy. 
Nevertheless, varying degrees of PBT-related 
toxicity may be inevitable. Eleven percent of pa-
tients with bladder/prostate rhabdomyosarcoma 
were reported to have developed grade 2 proctitis 
after PBT [12]. Ladra et al. [13] reported grade 3 
dermatitis and mucositis was observed in 9% and 
2%, respectively, after PBT. In this study, grade 3 
dermatitis and mucositis occurred in 15% and 25% 
of patients, respectively, which was more frequent 
than the previously reported rates. The high fre-
quency of head and neck RMS in this study may 
be one of the factors for the high incidence of acute 
toxicity because mucositis occurs more frequently 
in patients with head and neck lesions and in those 
who received irradiation to pelvic areas (Tab. 2). Pa-
tients concurrently undergoing radiotherapy with 
chemotherapy developed such acute toxicity more 
frequently than those not undergoing concurrent 
chemotherapy [8]. PBT is known to cause higher 
amounts of skin damage due to its characteristics 
than does photon therapy [14]. But there are no re-
ports about details of acute non-hematologic toxic-
ity of photon therapy in RMS. In our study, the fact 
that most of the patients (46 of 48) received concur-
rent chemotherapy may have resulted in the high 
incidence of toxicities. In addition, differences in 
genetic background in radiation sensitivity [15, 16] 
and difference in the chemotherapy regimen might 
influence the rate of acute toxicity. However, the 
table 5. patients’ outcomes
No.
3-year OS 3-year PFS 3-year LC
OS 95% CI p PFS 95% CI p LC 95% CI p
Total 48 0.942 0.864– 1.020 0.688 0.535– 0.841 0.793 0.666–0.920 
Irs-IV risk
Intermediate 42 0.970 0.911– 1.029 0.029 0.724 0.569– 0.879 0.239 0.793 0.656–0.930 
0.961 
high 6 0.833 0.535– 1.131 0.500 0.100– 0.900 0.800 0.449–1.151 
surgical treatment
radical resection 13 1.000 1.000– 1.000 0.465 0.653 0.375– 0.931 0.721 0.909 0.739–1.079 
0.548 conservative resection 8 0.833 0.535– 1.131 0.833 0.535–1.131 0.833 0.537–1.129 
Biopsy only 27 0.952 0.862– 1.042 0.676 0.476–0.876 0.729 0.546–0.912 
N — number; pFs — progression-free survival; Lc — local control; Os — overall survial; 95% cI — 95% confidence Interval; Irs-IV — Intergroup rhabdomyosarcoma 
study-IV
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Figure 3. Overall survival, progression-free survival, and local control rate according to surgical achievement. radical 
resection: n = 13; conservative resection: n = 8; biopsy only: n = 27. A. Overall survival calculated using the Kaplan-Meier 
method is shown. No significant differences were found among the 3 groups. b. progression-free survival calculated using the 
Kaplan-Meier method. is shown. No significant differences were found among the 3 groups. c. Local control rate calculated 
using the Kaplan-Meier method. Data according to the type of surgical therapy are shown. The local control rate tends to be 
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planned PBT was completed without a reduction in 
the dose or an increase in the rate of fever/elevation 
of CRP in this study. Furthermore, it is notable that 
grade 4 nonhematological toxicities were not ob-
served. These results indicate that PBT containing 
a therapeutic protocol is feasible for children with 
RMS under supportive care including appropriate 
application of opioids, granulocyte colony-stimu-
lating factor, antibiotics, and treatment for irradi-
ated skin according to the physician’s choice.
 The 3-year OS and PFS rates in this study were 
94.2% and 68.8%, respectively. And the 3-year 
OS and PFS rates were 97.0% and 72.4% in the 
intermediate-risk group and 83.3% and 50.0% in 
the high-risk group, respectively. In Japan, in 55 
children with newly diagnosed RMS who received 
PBT, 84.5% showed a 2-year OS [17]. In the COG 
trial, the 3-year PFS rates were 73% and 38% in the 
intermediate-risk group and the high-risk group, 
respectively [3, 4]. Ladra et al. [13] reported the 
5-year OS and EFS were 70% and 61% for interme-
diate-risk patients. Compared with these reports, 
better outcomes in terms of the OS and PFS of the 
high-risk group were observed in this study. Surgi-
cal resection is one of the important factors in the 
survival outcome of RMS patients [18, 19]. In this 
study, only 13 patients achieved radical resection, 
8 patients had conservative resection, and 27 had 
biopsy only. With this low surgical achievement, 
however, a fair 3-year OS rate was observed. Ad-
ditionally, no significant difference was observed 
in the PFS and LC rates among the 3 groups (Tab. 
5, Fig. 2). The relatively high radiation dose in pa-
tients who did not receive tumor resection possibly 
played some role in the prognosis (Fig. 1). Proton 
beam therapy enables sufficient irradiation to the 
target areas even if the tumor site is adjacent to 
vital organs. The treatment strategy of relatively 
high dosage to the unresectable tumors using PBT, 
which enabled markedly decreased normal tissue 
exposure while the high irradiation dose to the tu-
mor bed was maintained, as shown in Figure 2 and 
as indicated by previous dosimetric studies, might 
have contributed to the improved outcome in this 
study [12, 20, 21].
Reduction in the irradiation dose to normal tis-
sues in PBT may contribute to a decrease in the 
rate of occurrence of secondary malignancy. The 
cumulative incidence of subsequent malignant neo-
plasms (SMNs) exceeded 15–20% at 30 years after 
diagnosis of the primary cancer [22, 23]. Although 
no patient developed a solid tumor in this study, 
1 patient developed secondary MDS, which was 
diagnosed 2 years after the RMS diagnosis. Usually, 
chemotherapy-related MDS and acute myeloid leu-
kemia (t-MDS/AML) occur during a short period 
of latency (< 3–5 years from the primary cancer 
diagnosis), and the latency period for the develop-
ment of radiation-related solid SMNs exceeds 10 
years [24]. In addition to somatic mutations, germ-
line mutations in cancer predisposition genes may 
play an important role in the development of SMNs 
[23, 25]. Further prospective study with a larger 
cohort and with a longer follow-up period would 
be needed to assess the efficacy and safety of PBT in 
more detail, which may contribute to improvement 
in the prognosis of pediatric RMS patients. 
Although we discovered adverse events during 
PBT in RMS first time, our study have several limi-
tations: the number of patients is limited compared 
with previous studies; the distribution of the tumor 
sites are slightly different from other reports [2–4]; 
the follow-up period is relatively short to evaluate 
the late toxicities, especially SMNs
conclusion 
Multidisciplinary therapy containing PBT was 
feasible and can provide relatively fair 3-year PFS 
even in patients with surgically unresectable RMS 
without severe toxicity.
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